$ADPT

HERSHBERG ROBERT sold $748K of ADPT

HERSHBERG ROBERT sold 30,664 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $24.40 ($24.39–$24.41, $0.75M total) across 2 trades on 2026-08-18.

Original reporting
SEC EDGAR · HERSHBERG ROBERT
Published Aug 20, 2026, 9:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 9:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ADPT
Bearish
medium confidence
Mentioned
$ADPT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishLow
01

Why it matters

The insider sell reduces the director's ownership and may be interpreted as a negative signal, though the amount is modest relative to the company's market cap.

02

Market read

Primary disclosure of insider transaction; modest relevance for short-term traders.

03

What to watch

No disclosed 10b5-1 plan; the director may have personal liquidity needs.

Relevance 5/10Novelty 7/10Timing: post-market 2026-08-18

Background

Form 4 filing by Adaptive Biotechnologies director discloses a $748K share sale.

Company-level read

Ticker impact

$ADPTBearishMedium confidence
Context

Director Robert Hershberg sold 30,664 shares for $748K, reducing his stake to 46,683 shares.

Expected impact

Potential short-term downward pressure on ADPT stock.

Evidence & confidence

The sale size is notable for a director but not material enough to cause large price moves; traders may watch for further insider activity.

Market effects

Minimal impact on biotech sector; insider sell may be viewed as company-specific.

None

Low

Counterpoint

The sale could be unrelated to company fundamentals and merely portfolio rebalancing.

Key entities

  • Adaptive Biotechnologies Corp

    US-listed biotech company (ticker ADPT).

  • Robert Hershberg

    Director of Adaptive Biotechnologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTMed

Adaptive Biotechnologies Corp (ADPT): Results of Operations and Financial Condition

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results SEATTLE, Jul. 29, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene

$ADPTMedAI 9/10

Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026

Adaptive Biotechnologies (NASDAQ:ADPT) reported Q1 2026 revenue of $70.9 million, up 35% year over year, driven by its MRD business, which generated 95% of revenue and rose 53%. clonoSEQ test volume increased 41% to 32,595. Net loss narrowed to $20.0 million; non-GAAP Adjusted EBITDA loss was $2.5 million. The company raised full-year 2026 MRD revenue guidance to $260–$270 million.